Patients with heart failure with improved ejection fraction benefit from SGLT2 inhibitors

With modern treatments for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their heart function
during treatment.
But despite improvements in their hearts' ability to pump blood, these so-called heart failure patients with improved ejection fraction (HFimpEF) still had a high risk of
adverse outcomes.

Unfortunately, they are excluded from almost all clinical trials of heart failure, and there is little evidence on how best to improve the clinical management
of this growing patient population.

Brigham and Women's Hospital, one of the founding members of Brigham Massachusetts General Hospital, conducted an analysis by collaborators from the University of Minnesota and the University of Glasgow suggesting that this patient population may further benefit from the SGLT2 inhibitor dapagliflozin, a heart failure drug that received attention
following the release of data from the randomized controlled DELIVER clinical trial earlier this year 。 In a pre-specified data analysis from the DELIVER trial, the researchers looked at the outcomes of 1151 patients with HFPIF and found that dapagliflozin reduced the primary composite outcomes, first worsening heart failure events, cardiovascular death, and overall worsening heart failure events
.

Scott D.
Solomon, MD, co-corresponding author of BWH's Division of Cardiovascular Medicine, said, "This is essentially the first large-scale randomized outcome data
for patients with heart failure and improved ejection fraction.
" "This group is getting larger
as current treatments for heart failure that reduce ejection fraction get better and more patients show improvement.
These data suggest that the addition of SGLT2 inhibitors can benefit these patients and inform treatment decisions
.
”